Insider Selling: Sionna Therapeutics (NASDAQ:SION) Director Sells $1,978,583.88 in Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Bruce Booth sold 61,124 shares of the company’s stock in a transaction dated Friday, October 17th. The stock was sold at an average price of $32.37, for a total value of $1,978,583.88. Following the sale, the director owned 711,697 shares in the company, valued at $23,037,631.89. The trade was a 7.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Bruce Booth also recently made the following trade(s):

• On Tuesday, October 21st, Bruce Booth sold 88,878 shares of Sionna Therapeutics stock. The stock was sold at an average price of $34.22, for a total value of $3,041,405.16.
• On Thursday, October 16th, Bruce Booth sold 169,260 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.35, for a total transaction of $5,475,561.00.
• On Monday, October 20th, Bruce Booth sold 55,985 shares of Sionna Therapeutics stock. The stock was sold at an average price of $32.09, for a total value of $1,796,558.65.
• On Wednesday, October 15th, Bruce Booth sold 115,856 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.61, for a total value of $3,546,352.16.
• On Tuesday, October 14th, Bruce Booth sold 606 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $18,149.70.
• On Monday, October 13th, Bruce Booth sold 58,232 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.38, for a total value of $1,769,088.16.
• On Friday, October 10th, Bruce Booth sold 20,238 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.98, for a total value of $606,735.24.
• On Monday, October 6th, Bruce Booth sold 11,800 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $353,410.00.
• On Friday, October 3rd, Bruce Booth sold 37,746 shares of Sionna Therapeutics stock. The stock was sold at an average price of $30.00, for a total value of $1,132,380.00.
• On Wednesday, October 1st, Bruce Booth sold 200 shares of Sionna Therapeutics stock. The stock was sold at an average price of $29.95, for a total value of $5,990.00.

Sionna Therapeutics Stock Performance

Sionna Therapeutics stock opened at $38.90 on Thursday. The stock’s fifty day moving average price is $26.55 and its two-hundred day moving average price is $19.06. Sionna Therapeutics, Inc. has a one year low of $7.26 and a one year high of $43.19.

Sionna Therapeutics (NASDAQ:SION) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.41) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.27.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Royal Bank Of Canada assumed coverage on Sionna Therapeutics in a report on Wednesday, September 3rd. They set a “sector perform” rating and a $22.00 price objective on the stock. Jones Trading started coverage on Sionna Therapeutics in a report on Monday, September 8th. They set a “buy” rating and a $46.00 price objective on the stock. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 16th. Raymond James Financial started coverage on Sionna Therapeutics in a report on Tuesday, September 2nd. They set a “strong-buy” rating and a $45.00 target price on the stock. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Sionna Therapeutics in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $38.00.

Institutional Trading of Sionna Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SION. RA Capital Management L.P. bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $109,258,000. TPG GP A LLC bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $69,925,000. Atlas Venture Life Science Advisors LLC bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $38,639,000. Braidwell LP bought a new stake in Sionna Therapeutics during the 2nd quarter worth approximately $18,770,000. Finally, Jennison Associates LLC bought a new stake in Sionna Therapeutics during the 1st quarter worth approximately $8,995,000.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.